Suppr超能文献

甲状腺滤泡性肿瘤的免疫组织化学分析及BRAF突变相关性

Immunohistochemical analysis of thyroid follicular neoplasms and BRAF mutation correlation.

作者信息

Atik E, Guray M, Gunesacar R, Ozgur T, Canda T

机构信息

Department of Pathology, Mustafa Kemal University School of Medicine, Antakya/ Hatay, Turkey.

出版信息

Indian J Cancer. 2014 Jan-Mar;51(1):63-8. doi: 10.4103/0019-509X.134648.

Abstract

BACKGROUND

The accurate diagnosis of benign and malign thyroid tumors is very important for the clinical management of patients. The distinction of thyroid papillary carcinoma follicular variant and follicular adenoma can be difficult.

AIM

To investigate the alternative methods like immunohistochemistry and exon 15 in the BRAF gene 1799 T/A mutation analyses for distinguishing thyroid tumors.

MATERIALS AND METHODS

We applied immunohistochemical markers; CK19, HMWCK, Galectin-3, HBME-1 and Fibronectin and mutant allele-specific PCR amplification technique was used to determine 1799 T/A mutation within the BRAF gene. Formalin-fixed parafin embedded tissues from 45 surgically total resected thyroids, included 26 thyroid papillary carcinoma follicular variant (FV-TPC), 8 Follicular Adenoma (FA), 6 Minimal invasive follicular carcinoma (MIFC) and 5 Follicular Carcinoma (FC). Statistical Analyses Used: Pearson Chi-Square and Kruskal Wallis tests were performed.

RESULTS

There was a positive correlation between FV-TPC and HMWCK, CK 19, HBME1, Galectin 3, fibronectin (P < 0.05), but there was no correlation with FV-TPC and BRAF gene mutation (P > 0.05). HBME-1 and CK 19 stained strong and diffuse positive in FV-TPCs but weak and focal in FAs.

CONCLUSION

Our study suggests that morphologic features combined with immunohistochemical panel of HMWCK, CK19, HBME-1, Galectin-3 and fibronectin can help to distinguish benign and malign thyroid neoplasms and FV-TPC from follicular adenomas. BRAF gene 1799 T/A mutation has been non-specific but its detection can be a useful tool combined with immunohistochemistry for diagnosing FV-TPC.

摘要

背景

准确诊断甲状腺良恶性肿瘤对患者的临床治疗非常重要。甲状腺乳头状癌滤泡变体与滤泡性腺瘤的鉴别可能存在困难。

目的

研究免疫组织化学和BRAF基因1799T/A突变分析等替代方法在鉴别甲状腺肿瘤中的应用。

材料与方法

我们应用免疫组织化学标记物;细胞角蛋白19(CK19)、高分子量细胞角蛋白(HMWCK)、半乳糖凝集素-3(Galectin-3)、人甲状腺滤泡上皮细胞单克隆抗体(HBME-1)和纤连蛋白,并采用突变等位基因特异性PCR扩增技术检测BRAF基因内的1799T/A突变。45例手术全切除甲状腺的福尔马林固定石蜡包埋组织,包括26例甲状腺乳头状癌滤泡变体(FV-TPC)、8例滤泡性腺瘤(FA)、6例微小浸润性滤泡癌(MIFC)和5例滤泡癌(FC)。所用统计分析方法:进行Pearson卡方检验和Kruskal Wallis检验。

结果

FV-TPC与HMWCK、CK19、HBME1、Galectin 3、纤连蛋白之间呈正相关(P<0.05),但FV-TPC与BRAF基因突变无相关性(P>0.05)。HBME-1和CK19在FV-TPC中呈强弥漫性阳性,而在FA中呈弱局灶性阳性。

结论

我们的研究表明,形态学特征结合HMWCK、CK19、HBME-1、Galectin-3和纤连蛋白的免疫组织化学检测有助于鉴别甲状腺良恶性肿瘤以及FV-TPC与滤泡性腺瘤。BRAF基因1799T/A突变不具有特异性,但其检测结合免疫组织化学可作为诊断FV-TPC的有用工具。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验